ArticleAnalytical chemistry2026
Quantitative Multiplex Digital PCR with Fluorescence-Encoded Nanoreactor Beads.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syndromic PCR panels are becoming a pivotal diagnostic tool in precision medicine. Yet, the design and validation of such test panels is cumbersome, and the integration of new markers typically necessitates complete panel revalidation, a challenge that becomes even more complex for quantitative assays. Here, we introduce a novel multiplex digital PCR strategy utilizing fluorescence-encoded magnetic Nanoreactor Beads (femNRB), enabling cross-reactivity-free detection and absolute quantification of multiple genetic markers within a single sample. These uniquely encoded nanoreactor beads are reversibly conjugated to target-specific primers and probes, allowing the formation of highly adaptable panels composed of multiple PCR assays. As proof of concept, we assembled and validated a 10-assay panel targeting species-specific markers for common nosocomial pathogens. We subsequently expanded this panel with six additional markers for antibiotic resistance and virulence, systematically evaluating both configurations. Remarkably, without further optimization, both panels demonstrated equivalent analytical performance, underscoring the robustness and scalability of this method. This approach operates without complex microfluidic hardware and represents a diagnostic multiplex digital PCR platform that enables seamless assay integration while maintaining uncompromised quantification across variable sample concentrations. By eliminating the need for recalibration, this method substantially simplifies assay expansion, providing a powerful, modular solution for developing and upgrading diagnostic test panels with minimal effort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.